Clinical OMICS

JAN-FEB 2019

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link: https://clinicalomics.epubxp.com/i/1071882

Contents of this Issue

Navigation

Page 40 of 51

www.clinicalomics.com January/February 2019 Clinical OMICs 39 New Products Multiplex Test for Detection of Tick-Borne Pathogens Molecular testing company ChromaCode announced the commercial launch of the HDPCR Tick-Borne Pathogen (TBP) Panel, a multiplex PCR test that detects nine of the most common tick-borne pathogens in a single test. The launch marks the company's first multiplex test using its High Definition Polymerase Chain Reaction (HDPCR) technology. HDPCR multiplexing technology combines proprietary data science algorithms with widely-used, low-cost chemistries to increase the multiplexing levels of common real-time PCR (qPCR) and digital PCR (dPCR) instruments to allow for the simultaneous detection of between five and 50 targets in a single reaction. The TBP panel detects the most common tick-borne pathogens from whole blood specimens in under four hours. Features include a 3x increase in qPCR multiplexing, seamless integration onto common qPCR instrumentation, scalable throughput, and streamlined data analysis, management, and test customization with the ChromaCode Cloud software. ChromaCode www.chromacode.com Solid Tumor Profiling with Cloud-Based Informatics Clinical RNA sequencing and translational assay development company Cofactor Genomics released an RNA-based immune profiling kit developed for laboratories wishing to discover the immune composition of tumor samples. The ImmunoPrism Immune Profiling Kit provides users with access to the same kit Cofactor Genomics uses to prep, sequence and analyze against the company's database of machine-learning optimized immune reference expression models. The kit reports on significant im- mune modulatory molecules known to have implications in drug discovery, biomarker development and immunotherapy efficacy prediction. Speci fi cally, it provides the quantitative percentage for eight major immune cell types and expression levels of ten immune escape genes. This immune characterization can be obtained using FFPE, FNAs, or CNBs, accommodating solid tumors with very limited amounts of tissue—in some cases as low as 20 nanograms. This includes pre-treatment clinical samples, which previ- ously have been difficult to characterize. Cofactor Genomics www.cofactorgenomics.com Single-Cell Analysis for Proteogenomics, Immune Monitoring, and Library Prep Celsee has launched its first product, the Genesis system, that provides researchers with a platform to analyze and interpret cel- lular behavior and collect cell-based information that the compa- ny says was previously undetectable. Initial applications include proteogenomics, immune monitoring as an alternative to flow cy- tometry, and next-generation sequencing library preparation. The Genesis workflow achieves capture efficiencies of >70% and uses a gravity-based method to capture and isolate individual cells to maintain viability and structural integrity to improve the sensitiv- ity of single-cell analysis. The platform can be used directly with blood and tissue samples, offering a solution for understanding and mon- itoring cell-based diseases whether users are interested in studying an individual cell or millions of cells from a single sample. Celsee www.celsee.com Comprehensive, Accurate Pan-Cancer Tumor Profiling Illumina has launched its TruSight Oncology 500, a pan-cancer assay designed to measure tumor mutational burden (TMB) and microsatellite instability (MSI)—biomarkers that have shown po- tential for identifying new immunotherapies. TruSight Oncology 500 uses both DNA and RNA from tumor samples to identify so- matic variants underlying tumor progression, such as small DNA variants, fusions, and splice variants. The assay covers genes be- yond current cancer guidelines while covering 1.94Mb of the ge- nome to measure TMB. It also provides the ability to run RNA and DNA biomarkers into one workflow to enable labs to evaluate all relevant biomarkers at the same time. The tumor-only workflow provides cost savings for a lab since there is no need to run a nor- mal sample each time. TruSight Oncology 500 is for research use only and will ship in Q1 2019. Illumina www.illumina.com

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - JAN-FEB 2019